![Logo Cellaion 2 couleurs (PNG) Logo Cellaion 2 couleurs (PNG)](https://cellaion.com/wp-content/uploads/2022/02/Logo-Cellaion-2-couleurs-PNG-1024x496-717x348.png)
WHO WE ARE
Company
Cellaïon is a Belgian biotech company developing Life saving advanced therapies to repair tissues and regenerate the liver, Cellaïon targets life threatening diseases.
We are located in the biotech valley of the Walloon region in Belgium.
We are a team of biotech entrepreneurs, physicians and highly talented scientists in the field of liver diseases and cell based regenerative medicine.
Our strong IP base is issued from our own research and the academic research at UCLouvain, developed with the objective to generate new products.
Our lead product HepaStem® is in advanced clinical development in Acute on Chronic Liver Failure (ACLF), a life threatening condition affecting more than 100,000 patients worldwide each year, with a 50% mortality.
![Page en publication Page en publication](https://cellaion.com/wp-content/uploads/2022/02/Main-labo-1024x689-549x369.png)
The liver has an immense capacity to regenerate, but this process is often overwhelmed by the ongoing disease and by the tissue inflammation, with functional breakdown of the organ and impaired regenerative process.
We at Cellaion want to restore a favorable environment to reboost the regenerative process, and ensure a second life to the native liver instead of loosing it.
HepaStem® has a unique anti-inflammatory, immunomodulatory and regenerative capacity and is administered by a simple intravenous infusion.
TEAM
Management
Etienne SOKAL, M.D., Ph.D.
![M. Najimi Senior Research Associate at UCLouvain ; 27 years of experience in cell biology and expertise in isolating stem cells from tissues. Inventor of the technology and member of the founding laboratory.](https://cellaion.com/wp-content/uploads/2022/02/Capture-3-132x132.png)
![B. De Keersmaeker > 20 years of experience in operational, corporate and executive finance jobs in several industries as Biotech, construction, automotive, advertising and communication. Master degree in Economics from UCLouvain and a post-master MBA from Solvay Business School / ULB](https://cellaion.com/wp-content/uploads/2022/02/BDK-2022-3-905x1024-132x132.jpg)
TEAM
Board of Directors
Etienne SOKAL, Md, Ph.D.
Caroline THIELEN
Chris BUYSE
Pierre de WAHA
![Fouzia Laghrissi-Thode Dr. Fouzia Laghrissi-Thode, is currently the Chief Executive Officer of DalCor Pharmaceuticals. In her previous roles, she was the Vice-President at AstraZeneca of the US Renal-Cardiology Therapeutic Area and led the global product and portfolio strategy of the cardiovascular, metabolism and renal therapeutic areas at AstraZeneca and Roche. She has more than 20 years of pharmaceutical industry leadership experience in US and Europe through working in clinical development, global strategic marketing, business development, licensing and M&A. She is a director on the board of Minerva Neurosciences Inc., Nuro Corp., Smart Immune and DalCor Pharmaceuticals. She served as a board member of the Healthcare Businesswomen’s Association (HBA) Europe and was recognized by HBA in 2012 for her work in developing and promoting women leadership in healthcare. From 1992 to 2014, she held an appointment as faculty member at the University of Pittsburgh School of Medicine, UPMC, Western Psychiatric Institute and Clinic. Dr. Laghrissi-Thode is board certified in Psychiatry and holds Doctorate in Medicine from the University of Tours School of Medicine in France.](https://cellaion.com/wp-content/uploads/2022/03/Fouzia-Laghrissi-Thode-132x132.jpg)
Fouzia LAGHRISSI-THODE
OUR SCIENCE
What we do
We repair tissues and regenerate organs using cell signaling technology.
Our first target is the liver space. The liver is the master organ of the body, and loss of it’s function causes failure of other vital organs and death.
Cellaïon aims to stop progression of chronic liver disease, control infflammation, stop fibrous tissue accumulation and eventually allow organ recovery and regeneration.
Our lead compound HepaStem® acts as a therapeutic cargo, delivering to the liver and inflamed tissues appropriate immunomodulatory signals with specific anti-inflammatory, antifibrotic and regenerative activities.
Our treatment covers the wide spectrum of liver diseases, form the highly life threatening Acute on Chronic Liver Failure (ACLF) and Acute Alcoholic Hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases causes by Non Alcoholic Steato Hepatitis (NASH).
Genetic modification of HepaStem® allows to address specific targets in selected diseases.
Thanks to our allogeneic platform our of the shelf product and our multiple patients can be treated from one single tissues sourcing.
More than 100 patients have already received HepaStem®, easily administered by simple peripheral vein infusion, and the very high safety profile is now established with more that 10 years follow up.
Our proof of concept trial in ACLF is ongoing in many European countries and will be further extended in the US.
![References: Asrain SK et al. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171](https://cellaion.com/wp-content/uploads/2022/01/486-4866846_human-body-liver-png-transparent-png-removebg-preview-479x577.png)
References:
ACLF
Acute-on-chronic liver failure
Acute-on-Chronic Liver Failure (ACLF), a well characterized clinical entity affecting patients with chronic liver disease including cirrhosis, and characterized by a sudden deterioration of the liver, followed by other vital organs such as kidney, brain, lung or heart. ACLF has mortality from 42% up to 75% at 3 months.NASH
Non-alcoholic steato-hepatitis
Progressive Non-Alcoholic Steato-Hepatitis is the most severe manifestation of Non-alcoholic fatty liver disease (NAFLD). NASH is closely related to the triple epidemic of obesity, hyperlipidemia and diabetes type 2. The fat chronic deposits can induce liver injury and a sustained inflammation. NASH can progress to more serious disease stages, such as advanced fibrosis, cirrhosis or liver cancer.
AAH
Acute Alcoholic hepatitis
Acute Alcoholic Hepatitis is the inflammation of the liver caused by drinking excessive amounts of alcohol. The disease can be sudden with a high mortality rate.
AD
Acute Decompensated cirrhosis
Decompensated Cirrhosis is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterised by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome or variceal haemorrhage. Patients with AD can develop ACLF.
OUR SCIENCE
For Who
We care for the liver & we care for lives
The prevalence of CLD is more than 1.5 billion worldwide and cause more than 2 million deaths per year.
In European countries, the median cirrhosis prevalence was 833/100,000 (range 447-1100)(*)
The major and end complications of CLD are cirrhosis (1.2 million deaths) and liver cancer (790,000 deaths) – account for 3.5% of all deaths worldwide.
There is currently no approved treatment for these patients and only liver transplantation is considered as a last and unique hope.
PIPELINE
Our product: HepaStem®
![2022-10_13_Pipeline WEB_4 2022-10_13_Pipeline WEB_4](https://cellaion.com/wp-content/uploads/2022/10/2022-10_13_Pipeline-WEB_4-847x593.jpg)
HepaStem® platform.
PIPELINE
Clinical Trial
Publication:
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.
Published in April 2021 in JHEP Liver
![Page en publication Page en publication](https://cellaion.com/wp-content/uploads/2022/02/istockphoto-831942476-612x612-1-1014x676.jpg)
PIPELINE
Manufacturing
PARTNERSHIP
Collaborative projects
Current partnership
Cellaïon as partner
![Logo Cellaion 2 couleurs (PNG) Logo Cellaion 2 couleurs (PNG)](https://cellaion.com/wp-content/uploads/2022/10/Logo-Cellaion-2-couleurs-PNG-1024x496-178x85.png)